Market Segmentation:
- By Type
- Membranoproliferative Glomerulonephritis (MPGN)
- Dense Deposit Disease (DDD)
- C3 Glomerulonephritis (C3GN)
- Others (including Atypical Hemolytic Uremic Syndrome)
- By Treatment Type
- Immunosuppressive Therapies
- Plasma Therapies
- Complement Inhibitors
- Gene Therapies
- Kidney Transplantation
- Others (including symptomatic treatments)
- By Route of Administration
- Intravenous
- Oral
- Subcutaneous
- Others
- By End-User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others (including research institutes)
- By Mechanism of Action
- Complement C3 Inhibitors
- Complement C5 Inhibitors
- Complement Factor B Inhibitors
- Others (including anti-inflammatory agents)
- By Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the Complement 3 Glomerulopathy industry is USD 200 million.
Increasing prevalence of rare kidney diseases, Growing awareness about C3G, Rising healthcare expenditure
High treatment costs, Limited availability of approved therapies, Lack of awareness
The leading component segment in the Complement 3 Glomerulopathy Market is the Complement Inhibitors segment, which includes targeted therapies that inhibit the complement system to prevent kidney damage.
The major players operating in the Complement 3 Glomerulopathy Market are Alexion Pharmaceuticals, Chemocentryx, Omeros Corporation, Genentech, Novartis, Merck, AstraZeneca, Biocryst Pharmaceuticals, Biogen, and Amgen.
North America is expected to lead the Complement 3 Glomerulopathy Market, with a market share of 40.5% in 2023.
Advancements in diagnostic techniques, Development of novel targeted therapies